U.S. markets open in 3 hours 49 minutes
  • S&P Futures

    4,170.25
    -6.00 (-0.14%)
     
  • Dow Futures

    34,001.00
    -80.00 (-0.23%)
     
  • Nasdaq Futures

    14,028.75
    -0.75 (-0.01%)
     
  • Russell 2000 Futures

    2,246.70
    -12.30 (-0.54%)
     
  • Crude Oil

    63.07
    -0.06 (-0.10%)
     
  • Gold

    1,789.40
    +9.20 (+0.52%)
     
  • Silver

    26.22
    +0.11 (+0.44%)
     
  • EUR/USD

    1.2035
    +0.0055 (+0.46%)
     
  • 10-Yr Bond

    1.5730
    0.0000 (0.00%)
     
  • Vix

    17.06
    +0.49 (+2.96%)
     
  • GBP/USD

    1.3885
    +0.0046 (+0.33%)
     
  • USD/JPY

    108.0400
    -0.7430 (-0.68%)
     
  • BTC-USD

    57,032.95
    -556.79 (-0.97%)
     
  • CMC Crypto 200

    1,296.72
    -94.99 (-6.83%)
     
  • FTSE 100

    7,026.58
    +7.05 (+0.10%)
     
  • Nikkei 225

    29,685.37
    +2.00 (+0.01%)
     

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of NERV, GDRX and TCDA

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / February 2, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Minerva Neurosciences, Inc. (NASDAQ:NERV)

Investors Affected : May 15, 2017 - November 30, 2020

A class action has commenced on behalf of certain shareholders in Minerva Neurosciences, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the truth about the feedback received from the FDA concerning the “end-of-Phase 2” meeting; (ii) the Phase 2b study did not use the commercial formulation of roluperidone and was conducted solely outside of the United States; (iii) the failure of the Phase 3 study to meet its primary and key secondary endpoints rendered that study incapable of supporting substantial evidence of effectiveness; (iv) the Company's plan to use the combination of the Phase 2b and Phase 3 studies would be “highly unlikely” to support the submission of an NDA; (v) reliance on these two trials in the submission of an NDA would lead to “substantial review issues” because the trials were inadequate and not well-controlled; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/minerva-neurosciences-inc-loss-submission-form/?id=12619&from=1

GoodRx Holdings, Inc (NASDAQ:GDRX)

Investors Affected : September 23, 2020 - November 16, 2020

A class action has commenced on behalf of certain shareholders in GoodRx Holdings, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: at the time of the IPO, unbeknownst to investors, Amazon.com, Inc. was developing and would soon introduce its own online and mobile prescription medication ordering and fulfillment service that would directly compete with GoodRx. Defendants timed the IPO so that it was priced before Amazon announced its online pharmaceutical business to facilitate the IPO and create artificial demand for the common shares sold therein, as well to maximize the amount of money the Company and the selling stockholders could raise in the IPO. Given defendants' knowledge of Amazon's intention to enter the online pharmaceutical business, and their misleading statements about GoodRx's competitive position made contemporaneously with that knowledge, defendants' materially false and/or misleading statements alleged herein were made willfully and caused GoodRx common stock to trade at artificially inflated prices during the Class Period.

Shareholders may find more information at https://securitiesclasslaw.com/securities/goodrx-holdings-inc-loss-submission-form/?id=12619&from=1

Tricida, Inc. (NASDAQ:TCDA)

Investors Affected : September 4, 2019 - October 28, 2020

A class action has commenced on behalf of certain shareholders in Tricida, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Tricida's NDA for veverimer was materially deficient; (ii) accordingly, it was foreseeably likely that the FDA would not accept the NDA for veverimer; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/tricida-inc-loss-submission-form/?id=12619&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm



View source version on accesswire.com:
https://www.accesswire.com/627367/The-Gross-Law-Firm-Announces-Class-Actions-on-Behalf-of-Shareholders-of-NERV-GDRX-and-TCDA